John Hussman's ACAD Position Overview
John Hussman (via Hussman Strategic Advisors, Inc.) currently holds 147,000 shares of ACADIA Pharmaceuticals Inc. (ACAD) worth $3.93 M, representing 0.95% of the portfolio. First purchased in 2023-Q1, this medium-term investment has been held for 9 quarters.
Based on 13F filings, John Hussman has maintained a strategic position in ACAD, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 126,000 shares. Largest reduction occurred in Q3 2024, reducing 42,000 shares.
Analysis based on 13F filings available since 2013 Q2
John Hussman's ACADIA Pharmaceuticals (ACAD) Holding Value Over Time
Track share changes against reported price movement
Quarterly ACADIA Pharmaceuticals (ACAD) Trades by John Hussman
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2023 | +93,000 | New Buy | 93,000 | $18.82 |
| Q2 2023 | -31,000 | Reduce 33.33% | 62,000 | $23.95 |
| Q3 2023 | -20,000 | Reduce 32.26% | 42,000 | $20.84 |
| Q3 2024 | -42,000 | Sold Out | 0 | $0.00 |
| Q3 2025 | +126,000 | New Buy | 126,000 | $21.34 |
| Q4 2025 | +21,000 | Add 16.67% | 147,000 | $26.71 |
John Hussman's ACADIA Pharmaceuticals Investment FAQs
John Hussman first purchased ACADIA Pharmaceuticals Inc. (ACAD) in Q1 2023, acquiring 93,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman has held ACADIA Pharmaceuticals Inc. (ACAD) for 9 quarters since Q1 2023.
John Hussman's largest addition to ACADIA Pharmaceuticals Inc. (ACAD) was in Q3 2025, adding 126,000 shares worth $2.69 M.
According to the latest 13F filing for Q4 2025, John Hussman's firm, Hussman Strategic Advisors, Inc., owns 147,000 shares of ACADIA Pharmaceuticals Inc. (ACAD), valued at approximately $3.93 M.
As of the Q4 2025 filing, ACADIA Pharmaceuticals Inc. (ACAD) represents approximately 0.95% of John Hussman's publicly disclosed stock portfolio, making it one of their key holdings.
John Hussman's peak holding in ACADIA Pharmaceuticals Inc. (ACAD) was 147,000 shares, as reported at the end of Q4 2025.